Abstract: A metal material is provided with a bismuth coating which enables the subsequent coating to be accomplished at a high throwing power, and has excellent corrosion resistance, coating adhesion and is able to be produced with reduced damage to the environment. The metal material has a surface and a bismuth-containing layer deposited on at least a part of the surface of the metal material, wherein the percentage of bismuth atoms in the number of atoms in the surface layer of the metal material with a bismuth coating is at least 10%.

Abstract: Bismuth-containing compounds include bismuth and a biologically active agent coordinated to the bismuth. The biologically active agent includes at least one heteroatom configured for coordination with the bismuth. Coordination polymers include a polymer matrix that contains a bismuth-containing compound. Methods for modulating a pharmacokinetic property of a biologically active agent include coordinating the biologically active agent to bismuth to form a bismuth-containing compound, and administering the bismuth-containing compound orally to a patient. Methods for treating Parkinson's disease, methods for treating hypothyroidism, methods for treating ulcerative colitis, and methods for treating cancer each include administering a bismuth-containing compound to a patient.

Abstract: Arsenic compounds of general formula (I), their preparation methods, the pharmaceutical compositions containing the compounds, and their uses in the manufacture of medicaments for treating cancer, particularly leukemia, are disclosed.

Abstract: The present invention provides organometallic latent catalyst compounds, which are suitable as catalysts in polyaddition or polycondensation reactions which are catalysed by a Lewis acid type catalyst, in particular for the crosslinking of a blocked or unblocked isocyanate or isothiocyanate component with a polyol or polythiolto form a polyurethane (PU).

Abstract: Arsenic trioxide, an inorganic compound, is commercially available anti-cancer agent but it carries significant toxicity. Organic arsenicals, on the other hand, are much less toxic, to the extent that the methylation of inorganic arsenic in vivo into organic arsenicals has been considered a detoxification reaction. New organic arsenic derivatives have been synthesized, including S-dimethylarsino-glutathione, S-dimethylarsino-thiosuccinic acid and S-dimethylarsino-thiobenzoic acid, and established its potent in vitro cytotoxic activity against numerous human tumor cell lines, both of solid and hematological origin, as well as against malignant blood cells from patients with leukemia. Results form a basis for the development of S-dimethylarsino-glutathione, S-dimethylarsino-thiosuccinic acid, S-dimethylarsino-thiobenzoic acid, and other organic arsenicals as an anti-cancer therapy, combining high efficacy with very low, if any, toxicity.

Abstract: The present invention provides a composition and process using the composition for removing metal ions from aqueous process solutions. These compositions include a non-metallic compound and a suitable carrier. In one embodiment, the non-metallic compound is a thiuram. In another embodiment, the non-metallic compound can further include a dithiocarbamate. These compositions are contacted with the metal ions in the aqueous process solution having a wetting agent to form an organometallic complex precipitate. The precipitate can then be separated from the aqueous solution.

Abstract: Arsenic trioxide, an inorganic compound, is commercially available anti-cancer agent but it carries significant toxicity. Organic arsenicals, on the other hand, are much less toxic, to the extent that the methylation of inorganic arsenic in vivo into organic arsenicals has been considered a detoxification reaction. New organic arsenic derivatives have been synthesized, including S-dimethylarsino-glutathione, S-dimethylarsino-thiosuccinic acid and S-dimethylarsino-thiobenzoic acid, and established its potent in vitro cytotoxic activity against numerous human tumor cell lines, both of solid and hematological origin, as well as against malignant blood cells from patients with leukemia. Results form a basis for the development of S-dimethylarsino-glutathione, S-dimethylarsino-thiosuccinic acid, S-dimethylarsino-thiobenzoic acid, and other organic arsenicals as an anti-cancer therapy, combining high efficacy with very low, if any, toxicity.

Abstract: Arsenic trioxide, an inorganic compound, is commercially available anti-cancer agent but it carries significant toxicity. Organic arsenicals, on the other hand, are much less toxic, to the extent that the methylation of inorganic arsenic in vivo into organic arsenicals has been considered a detoxification reaction. New organic arsenic derivatives have been synthesized, including S-dimethylarsino-glutathione, S-dimethylarsino-thiosuccinic acid and S-dimethylarsino-thiobenzoic acid, and established its potent in vitro cytotoxic activity against numerous human tumor cell lines, both of solid and hematological origin, as well as against malignant blood cells from patients with leukemia. Results form a basis for the development of S-dimethylarsino-glutathione, S-dimethylarsino-thiosuccinic acid, S-dimethylarsino-thiobenzoic acid, and other organic arsenicals as an anti-cancer therapy, combining high efficacy with very low, if any, toxicity.

Abstract: A method for preparation of a semitransparent colloidal solution of bismuth sodium tartrate generally comprises producing an aqueous solution of bismuth sodium tartrate; extracting a magma of bismuth sodium tartrate from the aqueous solution at a pH of approximately 2.2; and then dissolving the magma into a salting-in mixture. After addition of preservative and strength testing, the base solution is diluted to elixir strength. The elixir is then buffered to a pH range of about 7.2 to about 7.3 in order to maintain for an extended duration the semitransparent nature of the elixir.

Abstract: A method for preparation of a semitransparent colloidal solution of bismuth sodium tartrate generally comprises producing an aqueous solution of bismuth sodium tartrate; extracting a magma of bismuth sodium tartrate from the aqueous solution at a pH of approximately 2.2; and then dissolving the magma into a salting-in mixture. It is critical that the magma be extracted at a pH of at least 2.2 but not more than 2.3. As a result, the magma is extracted by washing with a wash liquor comprising an addition of distilled water; allowing the magma to settle out of the wash liquor; measuring the pH of the wash liquor after the magma has settled; and then decanting the wash liquor from the magma. This process is then repeated as necessary to arrive at a magma within the critical pH range, whereafter the magma is air dried in preparation for salting-in. After addition of preservative and strength testing, the base solution is diluted to an elixir strength.

Abstract: A liquid precursor for forming a transparent metal oxide thin film comprises a first organic precursor compound. In one embodiment, the liquid precursor is for making a conductive thin film. In this embodiment, the liquid precursor contains a first metal from the group including tin, antimony, and indium dissolved in an organic solvent. The liquid precursor preferably comprises a second organic precursor compound containing a second metal from the same group. Also, the liquid precursor preferably comprises an organic dopant precursor compound containing a metal selected from the group including niobium, tantalum, bismuth, cerium, yttrium, titanium, zirconium, hafnium, silicon, aluminum, zinc and magnesium. Liquid precursors containing a plurality of metals have a longer shelf life. The addition of an organic dopant precursor compound containing a metal, such as niobium, tantalum or bismuth, to the liquid precursor enhances control of the conductivity of the resulting transparent conductor.

Abstract: An environmentally benign process for remediating contaminated matter includes contact with a lixiviant. The lixiviant contains a chelating agent which chemically reacts with a selected contaminant, forming a chelate soluble within the lixiviant and thus extracting the selected contaminant from the matter. The lixiviant, including the chelate, is separated from the particulate matter, and chemically treated to demobilize the chelate. The selected contaminant is separated from the lixiviant and sent for disposal or further processing. The remidiated matter is also sent for disposal or further processing.

Abstract: A method for preparation of a semitransparent colloidal solution of bismuth sodium tartrate generally comprises producing an aqueous solution of bismuth sodium tartrate; extracting a magma of bismuth sodium tartrate from the aqueous solution at a pH of approximately 2.2; and then dissolving the magma into a salting-in mixture. It is critical that the magma be extracted at a pH of at least 2.2 but not more than 2.3. As a result, the magma is extracted by washing with a wash liquor comprising an addition of distilled water; allowing the magma to settle out of the wash liquor; measuring the pH of the wash liquor after the magma has settled; and then decanting the wash liquor from the magma. This process is then repeated as necessary to arrive at a magma within the critical pH range, whereafter the magma is air dried in preparation for salting-in. After addition of preservative and strength testing, the base solution is diluted to an elixir strength.

Abstract: Enclosed are high refractive index and low birefringence organic/inorganic hybrid materials useful for optical applications. They are prepared from solventless metal aliphatic acryl alkoxides. The metal acryl alkoxides are synthesized from exchanging acryl alcohol with metal alkoxides, and are hydrolyzed into metal oxide nanoparticles and are well dispersed in the acrylate matrix. Then they are polymerized into organic/inorganic hybrid materials containing metal oxide in polyacrylate.

Abstract: A method for preparation of a semitransparent colloidal solution of bismuth sodium tartrate generally comprises producing an aqueous solution of bismuth sodium tartrate; extracting a magma of bismuth sodium tartrate from the aqueous solution at a pH of approximately 2.2; and then dissolving the magma into a salting-in mixture. It is critical that the magma be extracted at a pH of at least 2.2 but not more than 2.3. As a result, the magma is extracted by washing with a wash liquor comprising an addition of distilled water; allowing the magma to settle out of the wash liquor; measuring the pH of the wash liquor after the magma has settled; and then decanting the wash liquor from the magma. This process is then repeated as necessary to arrive at a magma within the critical pH range, whereafter the magma is air dried in preparation for salting-in. After addition of preservative and strength testing, the base solution is diluted to an elixir strength.

Abstract: A urethane (meth)acrylate metal salt obtained by reacting (A) one or more polyisocyanates, (B) one or more hydroxy functional (meth)acrylates, and (C) one or more metal salt polyols which are the reaction product of a metal oxide and a half ester containing a hydroxy group and a carboxylic acid group. Processes of preparing such salts and polymers prepared from such salts are also disclosed. The polymers are useful for coating and adhesive compositions prepared by radiation or peroxide curing processes.

Abstract: A liquid precursor for forming a transparent metal oxide thin film comprises a first organic precursor compound. In one embodiment, the liquid precursor is for making a conductive thin film. In this embodiment, the liquid precursor contains a first metal from the group including tin, antimony, and indium dissolved in an organic solvent. The liquid precursor preferably comprises a second organic precursor compound containing a second metal from the same group. Also, the liquid precursor preferably comprises an organic dopant precursor compound containing a metal selected from the group including niobium, tantalum, bismuth, cerium, yttrium, titanium, zirconium, hafnium, silicon, aluminum, zinc and magnesium. Liquid precursors containing a plurality of metals have a longer shelf life. The addition of an organic dopant precursor compound containing a metal, such as niobium, tantalum or bismuth, to the liquid precursor enhances control of the conductivity of the resulting transparent conductor.

Abstract: Cascade polymers, containing complex-forming ligands, optionally at least five ions of an element of atomic numbers 21-29, 39, 42, 44 or 57-83, as well as, if desired, cations of inorganic and/or organic bases, amino acids or amino acid amides, are valuable complexing compounds and complexes for diagnostics and therapy.

Abstract: The present invention provides for substituted metal chelating compounds in which at least two of the chelating atoms are nitrogen which are directly attached to aromatic rings and one or more of those nitrogen atoms has attached thereto a substituent other than hydrogen, and methods for making and using these compounds.

Abstract: Compounds which can chelate paramagnetic bi- and trivalent metal ions, their chelates with said metal ions and their use as contrast agents in magnetic resonance imaging (MRI), the compounds having formula (I) ##STR1## wherein R is a --(CH.sub.2).sub.m --O--R.sub.2 group or hydrogen,R.sub.2 is a (C.sub.6 -C.sub.10) aryl, or an alkyl(C.sub.1 -C.sub.5)-aryl(C.sub.6 -C.sub.10) group, substituted or not by a group L corresponding to a OH group or a OR.sub.3 group, wherein R.sub.3 is a linear or branched (C.sub.1 -C.sub.5) alkyl group; or L is NH.sub.2, halogen, COOH or CONR.sub.4 R.sub.5 wherein R.sub.4 and R.sub.5 are independently hydrogen, or a linear or branched (C.sub.1 -C.sub.5) alkyl which can be substituted by 1-6 hydroxy groups and/or 1-6 alkoxy groups,R.sub.1 can have the same meanings as R, independently from it, except for hydrogen,Z is independently OH or OR.sub.6, or NR.sub.4 R.sub.5 wherein R.sub.4 and R.sub.5 are as previously defined, and R.sub.6 is a (C.sub.1 -C.sub.

Abstract: The invention provides, as contrast signal generators in MR imaging of the digestive tract, paramagnetic metal chelates of novel acrylic compounds of formula C(R.sup.1 R.sup.2).dbd.CR.sup.3 --CO--Z--A (1) and/or C(R.sup.1 R.sup.2).dbd.CR.sup.3 --O--Z--A--Z--CO--CR.sup.3 .dbd.C(R.sup.1 R.sup.2) (2) in monomer, oligomer, homopolymer and copolymer forms, in which the R.sup.1, R.sup.2 and R.sup.3 represent H or saturated or unsaturated C.sub.1-10 aliphatic radicals optionally substituted by one or more OH groups; Z is a covalent bond or a linker spacer and A is a moiety capable of fixing a paramagnetic metal by chelation. Compounds of type (1) useful in the present invention are, for instance the polyalkylene-aminopolycaboxylic acids such as NTA, EDTA, DTPA, DOTA and like structures, possibly involving additional substituents; an example is the compound BOPTA which is a DTPA derivative carrying a benzyloxypropyl group.

Abstract: Cascade polymers, containing complex-forming ligands, optionally at least five ions of an element of atomic numbers 21-29, 39, 42, 44 or 57-83, as well as, if desired, cations of inorganic and/or organic bases, amino acids or amino acid amides, are valuable complexing compounds and complexes for diagnostics and therapy.

Abstract: The invention relates to a process for the production of metal-complex carboxylic acid amides, characterized in that a metal-complex carboxylic acid mixture that consists of the metal-complex carboxylic acid and at least one solubilizing substance in dimethyl sulfoxide (DMSO) is pretreated with a dehydrating reagent, optionally with the addition of a coupling adjuvant, and is then reacted with an amine of general formula IA(NH.sub.2).sub.n (I),in whichA stands for the radical of a natural or synthetic amine, andn stands for numbers 1 to 100.

Abstract: An essentially water-insoluble compound of bismuth and polyacrylic acid disperses well in the bowel and forms a good mucoadhesive covering of the bowel wall. Thus in patients with inflammatory bowel disease the bismuth is held in intimate contact to the inflamed tissue of the bowel. Two processes are provided for preparing said water-insoluble compounds.

Abstract: The present invention provides for substituted metal chelating compounds in which at least two of the chelating atoms are nitrogen which are directly attached to aromatic rings and one or more of those nitrogen atoms has attached thereto a substituent other than hydrogen, and methods for making and using these compounds.

Abstract: Disclosed are linear and cross-linked polymers suitable for use as a contrast agent for magnetic resonance imaging containing units comprising the residue of a poly(amine) moiety linked to a chelating agent and to one or more pendant (poly)alkylene oxides.

Abstract: There are provided polychelants and their metal chelates which are useful in diagnostic imaging and in radiotherapy and which comprise a plurality of macrocyclic chelant moieties, e.g. DOTA residues, conjugated to a dendritic polyamine backbone molecule, e.g. a starburst dendrimer. To produce a site-specific polychelate, one or more of the macrocyclic chelant carrying backbone molecules may be conjugated to a site-directed macromolecule, e.g. a protein.

Abstract: The invention relates to new, multiply substituted diethylenetriaminepentaacetic acid derivatives, their complexes and complex salts, that contain an element of atomic numbers 20-32, 39-51 or 57-83, pharmaceutical agents that contain these compounds, their use as contrast media and antidotes, and process for the production of pharmaceutical agents.

Abstract: The present invention relates to water-soluble, lipophilic contrast-enhancing agents, pharmaceutical compositions thereof and methods for diagnostic analysis, particularly NMR or MRI analysis using these contrast-enhancing agents. The water-soluble, lipophilic contrast-enhancing agents are chelates of a paramagnetic, ferromagnetic or diamagnetic metal ion(s) complexed with completing acids which contain at least one short-chain fatty acyl moiety having from about 0 to about 6 carbon atoms in its structure.

Abstract: A contrast enhancing agent for magnetic resonance images having a chelating agent, which can be bound to metals having at least one unpaired electron. Examples of such chelating agents include 3,6,9-tris(carboxymethyl)-1, 11-bis(dimethylamine)-3,6,9-triazaundecane; 3,6,9-tris(carboxymethyl)-1, 11-bis(diethanolamino) 3,6,9-triazaundecane; 3,6,9-tris(carboxymethyl)-1, 11-bis(tris(hydroymethyl) aminomethane)-3,6,9-triazaundecane; 3,6-bis(carboxymethyl-1,8-bis(N-carboxymethylglucosamino)-3,6-diazoctane; DTPA-bis(galactosamide), DTPA-Bis(glucosamide), DTPA-Bis(pyridoxamide), and poly-(DTPA-ethylenediamide).

Abstract: Compounds of general Formula I ##STR1## wherein Z.sup.1 and Z.sup.2 in each case independently mean the residue--(CH.sub.2).sub.m --(C.sub.6 H.sub.4).sub.q --(O).sub.k --(CH.sub.2).sub.n --(C.sub.6 H.sub.4).sub.l --(O).sub.r --R,whereinm and n means the numbers 0-20,k, l, q and r means the numbers 0 and 1, andR means a hydrogen atom, an optionally OR.sup.1 -substituted C.sub.1 -C.sub.6 -alkyl residue, or a CH.sub.2 COOR.sup.1 group with R.sup.1 meaning a hydrogen atom, a C.sub.1 -C.sub.6 -alkyl residue, or a benzyl group,with the proviso that at least two substituents X stand for a metal ion equivalent; that one of the substituents Z.sup.1 and Z.sup.2 stands for a hydrogen and the other is not H; that--if n and l each means the number 0--k and r do not simultaneously mean the number 1; that --(O).sub.r --R is not --OH; and that Z.sup.1 and Z.sup.2 are not --CH.sub.2 --C.sub.6 H.sub.4 --O--CH.sub.2 --COOCH.sub.2 C.sub.6 H.sub.5 or --CH.sub.2 --C.sub.6 H.sub.4 --O--(CH.sub.2).sub.5 --COOCH.sub.2 C.sub.6 H.sub.

Abstract: Novel complexes of paramagnetic ions and compounds bearing long acyl chains have been synthesized as magnetic resonance imaging contrast agents. These novel liposoluble contrast agents may be administered alone, or with lipids, suspending agents or other additives. The lipids may be in the form of liposomes, micelles or lipid emulsions. The contrast agents of the invention have particular use in magnetic resonance imaging of the liver, blood pool and reticuloendothelial system.

Abstract: An amphipathic polychelating compound including a hydrophilic polymeric moiety having a main backbone and a plurality of reactive side groups, a lipid-soluble anchor linked to the N terminal of the polymeric moiety, and a plurality of chelating agents linked to the side groups of the polymeric moiety. The polychelating compounds are bound to liposomes or micelles for use as diagnostic and therapeutic agents.

Abstract: The invention relates to new diethylenetriaminepentaacetic acid derivatives, their complexes and complex salts, that contain an element of atomic numbers 20-32, 39-51 or 57-83, pharmaceutical agents that contain these compounds and their use as contrast media and antidotes.

Abstract: The invention relates to diethylenetriaminepentaacetic acid monoamide derivatives, their complexes and complex salts, containing gadolinium, dysprosium, iron or manganese, pharmaceutical agents containing these compounds, their use as contrast media and process for their production.

Abstract: 1. Compounds of general Formula I ##STR1## wherein n and m in each case mean the numbers 0, 1, 2, 3 and 4,X stands for a hydrogen atom and/or a metal ion equivalent of an element of atomic numbers 21-29, 31, 32, 37-39, 42-44, 49 or 57-83,R.sup.1 and R.sup.2, being different, mean in each case a hydrogen atom or a straight-chain, branched, saturated or unsaturated C.sub.0 -C.sub.20 -alkylene group, this alkylene group exhibiting at the end either a second molecule of general Formula I.sub.A or I.sub.

Abstract: A method of forming a layered-perovskite bismuth-strontium-tantalum oxide (SBT) ferroelectric material is performed by dissolving a bismuth compound in a first solvent to form a first solution, mixing a strontium compound and a tantalum compound to form a binary mixture, dissolving the binary mixture in a second solvent to form a second solution, mixing the first solution with the second solution to form a SBT precursor solution, evaporating the first and second solvents to form a SBT precursor material and subsequently sintering said SBT precursor material in the presence of oxygen.

Abstract: Polymers comprising a ligand containing a carboxylic acid group, optionally at least one ion of an element of the atomic numbers 21-29, 42, 44 or 57-83 as well as optionally cations of inorganic and/or organic bases, amino acids or amino acid amides are valuable complexing agents and complexes for diagnosis.

Abstract: Metal complexes containing a metal of atomic numbers 39-42, 44-51 or 56-83 and a complexing agent can be used for the production of contrast media for use in the contrast-enhanced computer tomography of the liver and the biliary tracts.

Abstract: The present invention provides new and structurally diverse compositions comprising compounds of the general formula: ##STR1## Wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, and R.sup.5 are the same or different and are --CO--(CH.sub.2).sub.y --SH, --(CH.sub.2).sub.2 --SH, --SO.sub.2 --(SH.sub.2).sub.t --SH,--SH,--(CH.sub.2).sub.q --COOH, and --(CH.sub.2).sub.v --CONR.sup.6 R.sup.7, provided at least one of R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 is a sulfur containing moiety; n is 0 to about 10; i is 2 to about 5; j is 2 to about 5; y is 1 to about 5; z is 1 to about 6; t is 1 to about 5; q is 1 to about 5; v is 1 to about 5; R.sup.6 is H, alkyl, hydroxyalkyl, polyhydroxyalkyl, arylalkyl or alkoxyalkyl; R.sup.7 is H, alkyl, hydroxyalkyl, polyhydroxyalkyl, arylalkyl or alkoxyalkyl; and R.sup.7 can be polyamine when R.sup.6 is H.Methods for imaging using compositions of the invention are also provided.

Abstract: Metals are reacted in a first solvent, such as 2-methoxyethanol, to form an initial precursor comprising metal-oxide compounds dissolved in the first solvent. A second solvent, such as xylene, that does not react with the metal is added to the solution and the solution heated to distill away the first solvent and form a final precursor. The final precursor is spin-coated on an integrated circuit substrate then dried and annealed to form a thin film of a metal oxide. For metal oxides including bismuth, the bismuth precursor is added to a cold initial precursor and the final precursor is not heated after the bismuth precursor is added. The second solvent wets the substrate better than the first solvent and has a better viscosity for spin-coating, thus resulting in a denser thin film with fewer imperfections.

Abstract: Emulsions of paramagnetic contrast agents, and processes of making and using them are disclosed. The emulsions contain water, a dispersed oil phase and a complex of a paramagnetic metal ion and an organic chelator having a C.sub.10 -C.sub.30 unsaturated aliphatic group. The emulsions are very stable and therapeutically acceptable for intravenous administration to enhance MRI.

Abstract: Novel magnetic resonance imaging agents comprise complexes of paramagnetic ions with hydrazide derivatives of polyaminocarboxylic acid chelating agents. These novel imaging agents are characterized by excellent NMR image-contrasting properties and by high solubilities in physiological solutions. A novel method of performing an NMR diagnostic procedure involves administering to a warm-blooded animal an effective amount of a complex as described above and then exposing the warm-blooded animal to an NMR imaging procedure, thereby imaging at least a portion of the body of the warm-blooded animal.

Abstract: A second sphere contrast enhancing agent for magnetic resonance imaging comprises a paramagnetic metal ion having catecholate ligands coordinated thereto and having water molecules hydrogen bonded to the catecholate ligands.

Abstract: 1. Compounds of general Formula I ##STR1## wherein n and m in each case mean the numbers 0, 1, 2, 3 and 4,X stands for a hydrogen atom and/or a metal ion equivalent of an element of atomic numbers 21-29, 31, 32, 37-39, 42-44, 49 or 57-83,R.sup.1 and R.sup.2, being different, mean in each case a hydrogen atom or a straight-chain, branched, saturated or unsaturated C.sub.0 -C.sub.20 -alkylene group which optionally contains imino, phenylenoxy, phenylenimino, amido, hydrazido, ester group(s), oxygen, sulfur and/or nitrogen atom(s) and is substituted, if desired, by hydroxy, mercapto, imino, epoxy, oxo, thioxo and/or amino group(s), this alkylene group exhibiting at the end either a second molecule of general Formula I.sub.A or I.sub.B ##STR2## a functional group, or, linked by way of this functional group, a bio- or macromolecule,are valuable diagnostic and therapeutic media.

Abstract: Compositions comprisinga) a functional liquid or an internal combustion engine fuel andb) at least one compound of the general formula I ##STR1## wherein R.sub.1 is --(CH.sub.2 --X).sub.n R, where X=--S-- or --O--, n=0 or 1 to 18 carbon atoms, a phenyl group, a phenyl group which is substituted by at least one C.sub.1 -C.sub.18 alkyl group, a phenyl-C.sub.1 -C.sub.4 alkyl group or a phenyl-C.sub.1 -C.sub.4 alkyl group which is substituted by at least one C.sub.1 -C.sub.4 alkyl group, or R.sub.1 is an alkyl group of 1 to 18 carbon atoms which is substituted by at least one OH group, or R.sub.1 is a ##STR2## group in which the alkyl moiety contains 1 to 18 carbon atoms, and R.sub.2 and R.sub.3 are the same or different and are --H or, independently of R.sub.1, have the same meanings as R.sub.1, and M is B, Al, Fe, Cr, Sb or Bi, or M is a group M'--R' or a group M'--OR", where M' is Ti, Zr or Sn, and R' and R" is C.sub.1 -C.sub.18 alkyl or R' is ##STR3## wherein M' is defined above, and R.sub.1 ', R.sub.

Abstract: A polymeric contrast enhancing agent for magnetic resonance images having a chelating agent, which can be bound to metal ions having at least one unpaired electron, such as gadolinium. Examples of such chelating agents include DTPA-ethylenediamide-methacrylate copolymer and poly-(DTPA-ethylenediamide). These contrast enhancing agents, bound to the metal ions, are then administered to a patient, and following this the MR images are taken.

Abstract: The invention relates to a series of novel silicone fatty esters. This class of compounds, provide outstanding softening and lubricaton when applied to textiles and fibers. The compounds of the present invention are prepared by reacting a the terminal hydroxyl group in a silicone polymer with a fatty carboxylic acid, ester or anhydride.

Abstract: The peroxides which include the O.sup.17 isotope, especially the hydrogen peroxides and peroxides and hydroperoxides prepared therefrom, are well adapted as nonradioactive labeled compounds for use in the medicinal and biological arts.

Abstract: Macrocyclic derivatives of 1,4,7,10-tetraazacyclododecane of general formula (I) hereinbelow, wherein A is a group of formula (II) hereinbelow, in which R is H or alkyl or optionally substituted benzyl or a H(OCH.sub.2 CH.sub.2).sub.1-4-, Me(OCH.sub.2 CH.sub.2).sub.1-4-, or Et(OCH.sub.2 CH.sub.2).sub.1-4- group, X or O--R.sub.1, in which R.sub.1 is H or alkyl, hydroxyalkyl, alkoxyalkyl, alkoxyhydroxyalkyl or a polyoxaalkyl group or X is --NR.sub.2 R.sub.3, in which R.sub.2 and R.sub.3 are H or alkyl, hydroxyalkyl, alkoxyalkyl or alkoxyhydroxyalkyl, and B.sub.1, B.sub.2 and B.sub.3 have the same meanings as A or are H or a group of formula (III) hereinbelow, in which R.sub.4 is H or alkyl, Y is a O--R.sub.5 group, wherein R.sub.5 is H or alkyl, hydroxyalkyl, alkoxyalkyl, alkoxyhydroxyalkyl or a polyoxaalkyl group, or Y is a --NR.sub.6 R.sub.7 group, wherein R.sub.6 and R.sub.